Project Grant R43AI191788
Award Date
5/16/25
Completion Date
4/30/27
Dollars Obligated
$302K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Progenra Inc. (Z3JKMHXHFHJ6)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award, valued at $774,881, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop pro-apoptotic (cell death-inducing) drugs as host-directed therapies to shorten treatment for drug-susceptible and multi-drug resistant pulmonary tuberculosis (TB), as well as prevent post-TB lung disease. The project will leverage advanced in vivo imaging...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $265,650 to support research focused on developing modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis (TB). The award aims to (1) establish the structure-activity relationship and mechanism of action of the modified rifabutin analogs that have shown enhanced...
This federal Project Grant award, valued at $899,894 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research on understanding the interactions between macrophages, neutrophils, and HIV that contribute to tuberculosis (TB) disease progression. The key products and services to be delivered under this grant include: Defining the type I interferon (IFN) signaling and...
This federal Project Grant award of $447,009 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) categorize AM sensing abilities and defects using ex vivo and in vivo delivery of MTB-related pathogen associated molecular patterns (PAMPs),...
This $3,559,162 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to modulate indoleamines and optimize immunity in the setting of Mycobacterium tuberculosis (MTB)/HIV co-infection. The project, which runs from June 2024 to April 2029, aims to use macaque models of MTB/SIV co-infection to study the role of the IDO pathway in inhibiting effective immunity to TB and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $176,152 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rutgers, The State University of New Jersey. The grant supports research to identify new drug targets for treating drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study how alterations in lipid metabolism and host-pathogen interactions contribute to...
This federal Project Grant award of $817,405, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development and evaluation of new inhalational therapy regimens for the treatment of drug-sensitive and drug-resistant tuberculosis (TB). The key objectives are to: 1) manufacture and characterize a dry powder form of the spectinamide compound LEE-1810 for inhalation; 2) determine the...
This federal Project Grant award of $769,925.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the role of lung alveolar macrophage (AM) ontogeny and metabolism in regulating the permissiveness of AMs to Mycobacterium tuberculosis (MTB) infection. The research will utilize immunology, metabolism, genomics, microbiology, novel mouse models, and human primary AMs to understand how...
This Project Grant award, totaling $1,506,790, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to develop a highly-multiplexed CRISPR-based tuberculosis (TB) drug susceptibility test to improve accuracy and simplify workflows for TB drug resistance detection. Key objectives include: (1) developing a comprehensive CRISPR-based TB drug susceptibility test for predicting...